Verkhnyaya Radishchevskaya ulitsa, 12/19, 1
Eleventa is a private Russian biotech company founded in 2012 to develop and commercialize innovative products for the treatment of asthma and other allergic and inflammatory respiratory diseases.
Leading drug candidate O?000459, developed in partnership with the biotech company Oxagen, Ltd. (UK), is a small molecule compound active and selective antagonist of CRTH2 receptors that play a key role in initiating allergic inflammation. The drug has a significant anti-inflammatory effect and is used for the treatment of moderate to severe asthma and other respiratory allergies.
At the present time the company is due to complete a phase 3 clinical trial in patients with atopic eosinophilic asthma within the drug registration procedure in Russia.